Tickers

1. Composite Trajectory Verdict

For a professional services firm like FCN, the income statement carries the most weight because it reflects billing realization, utilization, and cost discipline, but the cash flow statement is equally critical due to the large, volatile forgivable-loan program that drives wedges between earnings and cash generation; the balance sheet is relevant mainly for leverage and buyback capacity.

Composite Trajectory: Mixed

Revenue grew modestly in FY2025 (+2.4% to $3.79B) and in Q2 2026 (+5.3% to $993M), but net income fell 3.3% annually and 19.4% quarterly. Operating income rose 12% annually but dropped 14% in Q2 2026. Operating cash flow collapsed 61.5% in FY2025 ($395M → $152M) due to a surge in forgivable loan issuances, yet rebounded sharply in H1 2026 (net cash used in operations improved from -$410M to -$158M). The balance sheet deteriorated rapidly: long-term debt went from $0 to $365M (Dec 2025) to $1.02B (Jun 2026) while equity fell from $2.26B to $1.73B to $1.33B, driven by $1.38B of share repurchases over three quarters. Earnings and balance sheet trends are weakening; cash flow is volatile but recently improving.

2. Red Flags

• Net income declining despite revenue growth: FY2025 revenue +2.4% ($3.79B vs $3.70B) but net income -3.3% ($271M vs $280M) (10-K 2025-12-31, Consolidated Statements of Operations).
• Operating cash flow collapse in FY2025: Net cash from operations fell 61.5% to $152M from $395M, driven by forgivable loan issuances of $297M vs $104M in FY2024 (10-K 2025-12-31, Consolidated Statements of Cash Flows; 10-K 2025-12-31, Note 12).
• Forgivable loan balances ballooning: Notes receivable from employees rose from $154M (Dec 2024) to $339M (Dec 2025) to $335M (Jun 2026), representing a large, illiquid asset tied to retention (10-K 2025-12-31, Note 12; 10-Q 2026-06-30, Consolidated Balance Sheets).
• Aggressive leveraging for buybacks: Long-term debt increased from $0 (Dec 2024) to $365M (Dec 2025) to $1.02B (Jun 2026) while stockholders’ equity dropped from $2.26B to $1.73B to $1.33B; $858.6M repurchased in FY2025 and $520M in H1 2026 (10-K 2025-12-31, Consolidated Balance Sheets; 10-Q 2026-06-30, Consolidated Balance Sheets; 10-Q 2026-06-30, MD&A).
• “Non-recurring” special charges recurring annually: $0 (FY2023), $8.2M (FY2024), $25.3M (FY2025) for workforce realignment (10-K 2025-12-31, Note 6).
• New extraordinary litigation expense added to non-GAAP adjustments: $6.6M in Q2 2026 for FTI vs. Orszag case, excluded from Adjusted EBITDA/EPS (10-Q 2026-06-30, MD&A; 10-Q 2026-06-30, Reconciliation of Net Income to Adjusted EBITDA).
• Widening GAAP-to-adjusted gap: Adjusted EBITDA exceeded net income by $124M in FY2024 and $193M in FY2025 (10-K 2025-12-31, Reconciliation of Net Income to Adjusted EBITDA).
• DSO deterioration sequentially: 88 days (Dec 2025) → 99 days (Jun 2026), though improved YoY from 100 days (Jun 2025) (10-K 2025-12-31, MD&A; 10-Q 2026-06-30, MD&A).

3. Earnings Assessment (Income Statement)

Earnings Trajectory: Mixed

Overall Assessment: FY2025 revenue rose 2.4% to $3.79B with operating income up 12% to $389M, but net income fell 3.3% to $271M due to higher interest expense ($21.4M vs $7.0M), higher tax provision ($100M vs $71M, effective rate 27.0% vs 20.2%), and special charges ($25.3M vs $8.2M) (10-K 2025-12-31, Consolidated Statements of Operations). Segment divergence widened: Corporate Finance (+11.5%) and FLC (+10.8%) grew, while Economic Consulting (-16.5%) and Technology (-10.5%) declined (10-K 2025-12-31, Segment Results). In Q2 2026, revenue rose 5.3% YoY to $993M, but operating income fell 14% to $85M and net income fell 19% to $58M, pressured by higher direct costs, SG&A, interest expense ($11.6M vs $5.3M), and $6.6M extraordinary litigation expenses (10-Q 2026-06-30, Consolidated Statements of Operations; 10-Q 2026-06-30, MD&A). Adjusted EBITDA margin compressed to 10.5% in Q2 2026 from 11.8% in Q2 2025 (10-Q 2026-06-30, Reconciliation of Net Income to Adjusted EBITDA).

4. Cash Generation Assessment (Statement of Cash Flows)

Cash Trajectory: Mixed

Overall Assessment: Annual operating cash flow has been volatile: $224M (FY2023) → $395M (FY2024) → $152M (FY2025), with the FY2025 drop driven by forgivable loan issuances ($297M vs $104M), higher compensation and tax payments (10-K 2025-12-31, Consolidated Statements of Cash Flows). Free cash flow followed: $175M → $360M → $94M (10-K 2025-12-31, Reconciliation of Net Cash Provided by Operating Activities to Free Cash Flow). However, the most recent comparable periods show strong improvement: Q2 2026 operating cash flow of $152M vs $56M in Q2 2025, and H1 2026 net cash used in operations of -$158M vs -$410M in H1 2025, reflecting lower loan issuances, higher collections, and lower tax payments (10-Q 2026-06-30, Consolidated Statements of Cash Flows; 10-Q 2026-06-30, MD&A). Quarterly free cash flow improved to $141M in Q2 2026 from $38M in Q2 2025 (10-Q 2026-06-30, Reconciliation of Net Cash Provided by Operating Activities to Free Cash Flow).

5. Balance Sheet Assessment

Balance Sheet Trajectory: Deteriorating

Overall Assessment: The balance sheet has weakened materially over the last 18 months. Cash fell from $660M (Dec 2024) to $265M (Dec 2025) to $164M (Jun 2026) (10-K 2025-12-31, Consolidated Balance Sheets; 10-Q 2026-06-30, Consolidated Balance Sheets). Total debt rose from zero to $365M (Dec 2025) to $1.02B (Jun 2026) via revolver drawdowns and a new $300M incremental term loan (10-K 2025-12-31, Note 13; 10-Q 2026-06-30, Note 8). Stockholders’ equity declined from $2.26B to $1.73B to $1.33B as $858.6M (FY2025) and $520M (H1 2026) were spent on buybacks (10-K 2025-12-31, Consolidated Statements of Stockholders’ Equity; 10-Q 2026-06-30, MD&A). Employee notes receivable grew from $154M to $339M to $335M, representing 9-10% of total assets (10-K 2025-12-31, Note 12; 10-Q 2026-06-30, Consolidated Balance Sheets). Total liabilities rose from $1.34B to $1.76B to $2.20B (10-K 2025-12-31, Consolidated Balance Sheets; 10-Q 2026-06-30, Consolidated Balance Sheets).

6. Data Gaps

• Individual quarterly income statements and cash flow statements for Q1 2026, Q3 2025, and Q4 2025 (only annual, Q2 2026, and YTD figures provided).
• Segment-level quarterly revenue, gross profit, and operating income for all five segments for Q1 2026, Q3 2025, Q4 2025.
• Detailed maturity schedule and interest rate breakdown for the $1.02B total debt outstanding at Jun 2026.
• Forgivable loan forgiveness schedule and expected future cash recovery profile.
• Covenant headroom calculations (consolidated total net leverage ratio) for each period.
• Breakdown of “Extraordinary Litigation-Related Expenses” beyond the $6.6M incurred in Q2 2026.
• Quarterly DSO and accounts receivable aging for periods other than period-end snapshots.